The global market for Transarterial Chemoembolization (TACE) was estimated to be worth US$ 10930 million in 2023 and is forecast to a readjusted size of US$ 18970 million by 2030 with a CAGR of 8.3% during the forecast period 2024-2030

Transarterial Chemoembolization (TACE) - Market

Trans-arterial Chemoembolization (TACE) is an interventional radiology procedure that delivers anti-cancer medication (chemotherapy) and embolizing materials directly into blood vessels feeding a malignant liver tumor. TACE is a two-pronged approach that can simultaneously limit the blood supply feeding a tumor in order to destroy cancerous cells (embolization) while the chemotherapy prevents further growth.Transarterial Chemoembolization (TACE) is a minimally invasive procedure in which chemotherapy and embolic agents are directly delivered to a cancerous tumour via its blood supply. The embolic agents are used to cut off the blood supply to the tumour without affecting the rest of the liver. Compared to receiving conventional chemotherapy, TACE allows for the maximum amount of chemotherapy agent to reach the tumour, while limiting the amount released into the bloodstream.

The global Transarterial Chemoembolization (TACE) market refers to the market for a minimally invasive procedure used in the treatment of liver cancer. TACE is a locoregional therapy that combines chemotherapy and embolization to deliver anticancer drugs directly to the tumor site while blocking the blood supply to the tumor.

Liver cancer, specifically hepatocellular carcinoma (HCC), is a leading cause of cancer-related deaths worldwide. TACE has emerged as a commonly used treatment option for patients with intermediate-stage HCC or those who are not eligible for surgical resection or liver transplantation.

The TACE procedure involves the insertion of a catheter into the hepatic artery, the main blood supply to the liver. Through the catheter, a drug-eluting bead or emulsion containing chemotherapeutic agents is infused directly into the tumor, followed by the injection of embolic agents to occlude the blood vessels feeding the tumor. This dual action targets the tumor cells and restricts their blood supply, thereby delaying tumor growth and potentially shrinking the tumor.

Some key factors driving the global TACE market include:

Increasing incidence of liver cancer: The rising prevalence of liver cancer, particularly HCC, has led to an increased demand for effective treatment options. TACE offers a targeted approach for patients with intermediate-stage HCC, who represent a significant portion of liver cancer cases.

Limited surgical options: Liver resection and transplantation remain the most effective treatment options for early-stage HCC. However, many patients are not eligible for surgery due to the size and location of the tumor, underlying liver disease, or other patient factors. TACE provides a non-surgical alternative for these patients.

Advancements in imaging and catheterization techniques: The advancements in imaging technologies, such as computed tomography (CT) and fluoroscopy, have improved the precision and safety of TACE procedures. Additionally, the development of better catheterization techniques and embolic agents has enhanced the effectiveness and outcomes of TACE.

Multidisciplinary approach to cancer treatment: TACE is often used as part of a multidisciplinary approach to treating liver cancer. It may be combined with other interventions, such as radiofrequency ablation, sorafenib therapy, or immunotherapy, to achieve better treatment outcomes.

The global TACE market includes various players, including medical device manufacturers, pharmaceutical companies, and healthcare providers offering TACE equipment, drugs, and related services. Additionally, research and development activities are continually focused on improving the effectiveness and safety of TACE procedures and developing innovative embolic agents and drug formulations.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Transarterial Chemoembolization (TACE), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Transarterial Chemoembolization (TACE) by region & country, by Type, and by Application.

The Transarterial Chemoembolization (TACE) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transarterial Chemoembolization (TACE).

Market Segmentation

Scope of Transarterial Chemoembolization (TACE) - Market Report

Report Metric	Details
Report Name	Transarterial Chemoembolization (TACE) - Market
Forecasted market size in 2030	US$ 18970 million
CAGR	8.3%
Forecasted years	2024 - 2030
Segment by Type:	Chemotherapeutic Agents Radio Therapeutic Agents Drug-eluting Particles Others
Segment by Application	Hospitals Clinics Cancer Research Centers
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG, Pfizer Inc., Spectrum Pharmaceutical, Roche Holding AG, Celgene, Bayer AG, Merck & Co., Inc., SingHealth
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Transarterial Chemoembolization (TACE) manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Transarterial Chemoembolization (TACE) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Transarterial Chemoembolization (TACE) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Transarterial Chemoembolization (TACE) - Market size in 2030?

Ans: The Transarterial Chemoembolization (TACE) - Market size in 2030 will be US$ 18970 million.

Who are the main players in the Transarterial Chemoembolization (TACE) - Market report?

Ans: The main players in the Transarterial Chemoembolization (TACE) - Market are Questex, Siemens Healthcare GmbH, Bellicum Pharmaceuticals Inc., Boston Scientific, Cook Group, Hikma Pharmaceuticals, Nippon Kayaku, Novartis AG, Pfizer Inc., Spectrum Pharmaceutical, Roche Holding AG, Celgene, Bayer AG, Merck & Co., Inc., SingHealth

What are the Application segmentation covered in the Transarterial Chemoembolization (TACE) - Market report?

Ans: The Applications covered in the Transarterial Chemoembolization (TACE) - Market report are Hospitals, Clinics, Cancer Research Centers

What are the Type segmentation covered in the Transarterial Chemoembolization (TACE) - Market report?

Ans: The Types covered in the Transarterial Chemoembolization (TACE) - Market report are Chemotherapeutic Agents, Radio Therapeutic Agents, Drug-eluting Particles, Others

1 Market Overview

1.1 Transarterial Chemoembolization (TACE) Product Introduction

1.2 Global Transarterial Chemoembolization (TACE) Market Size Forecast

1.3 Transarterial Chemoembolization (TACE) Market Trends & Drivers

1.3.1 Transarterial Chemoembolization (TACE) Industry Trends

1.3.2 Transarterial Chemoembolization (TACE) Market Drivers & Opportunity

1.3.3 Transarterial Chemoembolization (TACE) Market Challenges

1.3.4 Transarterial Chemoembolization (TACE) Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Transarterial Chemoembolization (TACE) Players Revenue Ranking (2023)

2.2 Global Transarterial Chemoembolization (TACE) Revenue by Company (2019-2024)

2.3 Key Companies Transarterial Chemoembolization (TACE) Manufacturing Base Distribution and Headquarters

2.4 Key Companies Transarterial Chemoembolization (TACE) Product Offered

2.5 Key Companies Time to Begin Mass Production of Transarterial Chemoembolization (TACE)

2.6 Transarterial Chemoembolization (TACE) Market Competitive Analysis

2.6.1 Transarterial Chemoembolization (TACE) Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Transarterial Chemoembolization (TACE) Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transarterial Chemoembolization (TACE) as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Chemotherapeutic Agents

3.1.2 Radio Therapeutic Agents

3.1.3 Drug-eluting Particles

3.1.4 Others

3.2 Global Transarterial Chemoembolization (TACE) Sales Value by Type

3.2.1 Global Transarterial Chemoembolization (TACE) Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Transarterial Chemoembolization (TACE) Sales Value, by Type (2019-2030)

3.2.3 Global Transarterial Chemoembolization (TACE) Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospitals

4.1.2 Clinics

4.1.3 Cancer Research Centers

4.2 Global Transarterial Chemoembolization (TACE) Sales Value by Application

4.2.1 Global Transarterial Chemoembolization (TACE) Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Transarterial Chemoembolization (TACE) Sales Value, by Application (2019-2030)

4.2.3 Global Transarterial Chemoembolization (TACE) Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Transarterial Chemoembolization (TACE) Sales Value by Region

5.1.1 Global Transarterial Chemoembolization (TACE) Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Transarterial Chemoembolization (TACE) Sales Value by Region (2019-2024)

5.1.3 Global Transarterial Chemoembolization (TACE) Sales Value by Region (2025-2030)

5.1.4 Global Transarterial Chemoembolization (TACE) Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

5.2.2 North America Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

5.3.2 Europe Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

5.4.2 Asia Pacific Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

5.5.2 South America Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

5.6.2 Middle East & Africa Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Transarterial Chemoembolization (TACE) Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Transarterial Chemoembolization (TACE) Sales Value

6.3 United States

6.3.1 United States Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

6.3.2 United States Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

6.4.2 Europe Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

6.5.2 China Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

6.5.3 China Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

6.6.2 Japan Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

6.7.2 South Korea Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

6.8.2 Southeast Asia Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Transarterial Chemoembolization (TACE) Sales Value, 2019-2030

6.9.2 India Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

6.9.3 India Transarterial Chemoembolization (TACE) Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Questex

7.1.1 Questex Profile

7.1.2 Questex Main Business

7.1.3 Questex Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.1.4 Questex Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.1.5 Questex Recent Developments

7.2 Siemens Healthcare GmbH

7.2.1 Siemens Healthcare GmbH Profile

7.2.2 Siemens Healthcare GmbH Main Business

7.2.3 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.2.4 Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.2.5 Siemens Healthcare GmbH Recent Developments

7.3 Bellicum Pharmaceuticals Inc.

7.3.1 Bellicum Pharmaceuticals Inc. Profile

7.3.2 Bellicum Pharmaceuticals Inc. Main Business

7.3.3 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.3.4 Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.3.5 Boston Scientific Recent Developments

7.4 Boston Scientific

7.4.1 Boston Scientific Profile

7.4.2 Boston Scientific Main Business

7.4.3 Boston Scientific Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.4.4 Boston Scientific Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.4.5 Boston Scientific Recent Developments

7.5 Cook Group

7.5.1 Cook Group Profile

7.5.2 Cook Group Main Business

7.5.3 Cook Group Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.5.4 Cook Group Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.5.5 Cook Group Recent Developments

7.6 Hikma Pharmaceuticals

7.6.1 Hikma Pharmaceuticals Profile

7.6.2 Hikma Pharmaceuticals Main Business

7.6.3 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.6.4 Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.6.5 Hikma Pharmaceuticals Recent Developments

7.7 Nippon Kayaku

7.7.1 Nippon Kayaku Profile

7.7.2 Nippon Kayaku Main Business

7.7.3 Nippon Kayaku Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.7.4 Nippon Kayaku Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.7.5 Nippon Kayaku Recent Developments

7.8 Novartis AG

7.8.1 Novartis AG Profile

7.8.2 Novartis AG Main Business

7.8.3 Novartis AG Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.8.4 Novartis AG Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.8.5 Novartis AG Recent Developments

7.9 Pfizer Inc.

7.9.1 Pfizer Inc. Profile

7.9.2 Pfizer Inc. Main Business

7.9.3 Pfizer Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.9.4 Pfizer Inc. Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.9.5 Pfizer Inc. Recent Developments

7.10 Spectrum Pharmaceutical

7.10.1 Spectrum Pharmaceutical Profile

7.10.2 Spectrum Pharmaceutical Main Business

7.10.3 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.10.4 Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.10.5 Spectrum Pharmaceutical Recent Developments

7.11 Roche Holding AG

7.11.1 Roche Holding AG Profile

7.11.2 Roche Holding AG Main Business

7.11.3 Roche Holding AG Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.11.4 Roche Holding AG Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.11.5 Roche Holding AG Recent Developments

7.12 Celgene

7.12.1 Celgene Profile

7.12.2 Celgene Main Business

7.12.3 Celgene Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.12.4 Celgene Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.12.5 Celgene Recent Developments

7.13 Bayer AG

7.13.1 Bayer AG Profile

7.13.2 Bayer AG Main Business

7.13.3 Bayer AG Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.13.4 Bayer AG Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.13.5 Bayer AG Recent Developments

7.14 Merck & Co., Inc.

7.14.1 Merck & Co., Inc. Profile

7.14.2 Merck & Co., Inc. Main Business

7.14.3 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.14.4 Merck & Co., Inc. Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.14.5 Merck & Co., Inc. Recent Developments

7.15 SingHealth

7.15.1 SingHealth Profile

7.15.2 SingHealth Main Business

7.15.3 SingHealth Transarterial Chemoembolization (TACE) Products, Services and Solutions

7.15.4 SingHealth Transarterial Chemoembolization (TACE) Revenue (US$ Million) & (2019-2024)

7.15.5 SingHealth Recent Developments

8 Industry Chain Analysis

8.1 Transarterial Chemoembolization (TACE) Industrial Chain

8.2 Transarterial Chemoembolization (TACE) Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Transarterial Chemoembolization (TACE) Sales Model

8.5.2 Sales Channel

8.5.3 Transarterial Chemoembolization (TACE) Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Questex

Siemens Healthcare GmbH

Bellicum Pharmaceuticals Inc

Boston Scientific

Cook Group

Hikma Pharmaceuticals

Nippon Kayaku

Novartis

Pfizer Inc

Spectrum Pharmaceutical

List of Tables

Table 1. Transarterial Chemoembolization (TACE) Market Trends

Table 2. Transarterial Chemoembolization (TACE) Market Drivers & Opportunity

Table 3. Transarterial Chemoembolization (TACE) Market Challenges

Table 4. Transarterial Chemoembolization (TACE) Market Restraints

Table 5. Global Transarterial Chemoembolization (TACE) Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Transarterial Chemoembolization (TACE) Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Transarterial Chemoembolization (TACE) Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Transarterial Chemoembolization (TACE) Product Type

Table 9. Key Companies Time to Begin Mass Production of Transarterial Chemoembolization (TACE)

Table 10. Global Transarterial Chemoembolization (TACE) Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transarterial Chemoembolization (TACE) as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Transarterial Chemoembolization (TACE) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Transarterial Chemoembolization (TACE) Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Transarterial Chemoembolization (TACE) Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Transarterial Chemoembolization (TACE) Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Transarterial Chemoembolization (TACE) Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Transarterial Chemoembolization (TACE) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Transarterial Chemoembolization (TACE) Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Transarterial Chemoembolization (TACE) Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Transarterial Chemoembolization (TACE) Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Transarterial Chemoembolization (TACE) Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Transarterial Chemoembolization (TACE) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Transarterial Chemoembolization (TACE) Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Transarterial Chemoembolization (TACE) Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Transarterial Chemoembolization (TACE) Sales Value by Region (2019-2024) & (%)

Table 27. Global Transarterial Chemoembolization (TACE) Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Transarterial Chemoembolization (TACE) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Transarterial Chemoembolization (TACE) Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Transarterial Chemoembolization (TACE) Sales Value, (2025-2030) & (US$ Million)

Table 31. Questex Basic Information List

Table 32. Questex Description and Business Overview

Table 33. Questex Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 34. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Questex (2019-2024)

Table 35. Questex Recent Developments

Table 36. Siemens Healthcare GmbH Basic Information List

Table 37. Siemens Healthcare GmbH Description and Business Overview

Table 38. Siemens Healthcare GmbH Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 39. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Siemens Healthcare GmbH (2019-2024)

Table 40. Siemens Healthcare GmbH Recent Developments

Table 41. Bellicum Pharmaceuticals Inc. Basic Information List

Table 42. Bellicum Pharmaceuticals Inc. Description and Business Overview

Table 43. Bellicum Pharmaceuticals Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 44. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Bellicum Pharmaceuticals Inc. (2019-2024)

Table 45. Bellicum Pharmaceuticals Inc. Recent Developments

Table 46. Boston Scientific Basic Information List

Table 47. Boston Scientific Description and Business Overview

Table 48. Boston Scientific Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 49. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Boston Scientific (2019-2024)

Table 50. Boston Scientific Recent Developments

Table 51. Cook Group Basic Information List

Table 52. Cook Group Description and Business Overview

Table 53. Cook Group Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 54. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Cook Group (2019-2024)

Table 55. Cook Group Recent Developments

Table 56. Hikma Pharmaceuticals Basic Information List

Table 57. Hikma Pharmaceuticals Description and Business Overview

Table 58. Hikma Pharmaceuticals Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 59. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Hikma Pharmaceuticals (2019-2024)

Table 60. Hikma Pharmaceuticals Recent Developments

Table 61. Nippon Kayaku Basic Information List

Table 62. Nippon Kayaku Description and Business Overview

Table 63. Nippon Kayaku Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 64. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Nippon Kayaku (2019-2024)

Table 65. Nippon Kayaku Recent Developments

Table 66. Novartis AG Basic Information List

Table 67. Novartis AG Description and Business Overview

Table 68. Novartis AG Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 69. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Novartis AG (2019-2024)

Table 70. Novartis AG Recent Developments

Table 71. Pfizer Inc. Basic Information List

Table 72. Pfizer Inc. Description and Business Overview

Table 73. Pfizer Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 74. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Pfizer Inc. (2019-2024)

Table 75. Pfizer Inc. Recent Developments

Table 76. Spectrum Pharmaceutical Basic Information List

Table 77. Spectrum Pharmaceutical Description and Business Overview

Table 78. Spectrum Pharmaceutical Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 79. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Spectrum Pharmaceutical (2019-2024)

Table 80. Spectrum Pharmaceutical Recent Developments

Table 81. Roche Holding AG Basic Information List

Table 82. Roche Holding AG Description and Business Overview

Table 83. Roche Holding AG Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 84. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Roche Holding AG (2019-2024)

Table 85. Roche Holding AG Recent Developments

Table 86. Celgene Basic Information List

Table 87. Celgene Description and Business Overview

Table 88. Celgene Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 89. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Celgene (2019-2024)

Table 90. Celgene Recent Developments

Table 91. Bayer AG Basic Information List

Table 92. Bayer AG Description and Business Overview

Table 93. Bayer AG Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 94. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Bayer AG (2019-2024)

Table 95. Bayer AG Recent Developments

Table 96. Merck & Co., Inc. Basic Information List

Table 97. Merck & Co., Inc. Description and Business Overview

Table 98. Merck & Co., Inc. Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 99. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of Merck & Co., Inc. (2019-2024)

Table 100. Merck & Co., Inc. Recent Developments

Table 101. SingHealth Basic Information List

Table 102. SingHealth Description and Business Overview

Table 103. SingHealth Transarterial Chemoembolization (TACE) Products, Services and Solutions

Table 104. Revenue (US$ Million) in Transarterial Chemoembolization (TACE) Business of SingHealth (2019-2024)

Table 105. SingHealth Recent Developments

Table 106. Key Raw Materials Lists

Table 107. Raw Materials Key Suppliers Lists

Table 108. Transarterial Chemoembolization (TACE) Downstream Customers

Table 109. Transarterial Chemoembolization (TACE) Distributors List

Table 110. Research Programs/Design for This Report

Table 111. Key Data Information from Secondary Sources

Table 112. Key Data Information from Primary Sources

Table 113. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Transarterial Chemoembolization (TACE) Product Picture

Figure 2. Global Transarterial Chemoembolization (TACE) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Transarterial Chemoembolization (TACE) Sales Value (2019-2030) & (US$ Million)

Figure 4. Transarterial Chemoembolization (TACE) Report Years Considered

Figure 5. Global Transarterial Chemoembolization (TACE) Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Transarterial Chemoembolization (TACE) Revenue in 2023

Figure 7. Transarterial Chemoembolization (TACE) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Chemotherapeutic Agents Picture

Figure 9. Radio Therapeutic Agents Picture

Figure 10. Drug-eluting Particles Picture

Figure 11. Others Picture

Figure 12. Global Transarterial Chemoembolization (TACE) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global Transarterial Chemoembolization (TACE) Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Hospitals

Figure 15. Product Picture of Clinics

Figure 16. Product Picture of Cancer Research Centers

Figure 17. Global Transarterial Chemoembolization (TACE) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Transarterial Chemoembolization (TACE) Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Transarterial Chemoembolization (TACE) Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Transarterial Chemoembolization (TACE) Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Transarterial Chemoembolization (TACE) Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Transarterial Chemoembolization (TACE) Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Transarterial Chemoembolization (TACE) Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Transarterial Chemoembolization (TACE) Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Transarterial Chemoembolization (TACE) Sales Value (%), (2019-2030)

Figure 30. United States Transarterial Chemoembolization (TACE) Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Transarterial Chemoembolization (TACE) Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Transarterial Chemoembolization (TACE) Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Transarterial Chemoembolization (TACE) Sales Value by Application (%), 2023 VS 2030

Figure 36. China Transarterial Chemoembolization (TACE) Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

Figure 38. China Transarterial Chemoembolization (TACE) Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Transarterial Chemoembolization (TACE) Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Transarterial Chemoembolization (TACE) Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Transarterial Chemoembolization (TACE) Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Transarterial Chemoembolization (TACE) Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Transarterial Chemoembolization (TACE) Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Transarterial Chemoembolization (TACE) Sales Value by Application (%), 2023 VS 2030

Figure 48. India Transarterial Chemoembolization (TACE) Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Transarterial Chemoembolization (TACE) Sales Value by Type (%), 2023 VS 2030

Figure 50. India Transarterial Chemoembolization (TACE) Sales Value by Application (%), 2023 VS 2030

Figure 51. Transarterial Chemoembolization (TACE) Industrial Chain

Figure 52. Transarterial Chemoembolization (TACE) Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-6T7647

Tue Oct 08 00:00:00 UTC 2024

Add to Cart

Anti-Oral Mucositis Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-5V5924

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Transarterial Chemoembolization (TACE) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-18Y13983

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

Multiple Myeloma Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37R6886

Mon Oct 07 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Transarterial Chemoembolization (TACE) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: October 2024

Report Code: QYRE-Auto-18Y13983

Transarterial Chemoembolization (TACE) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

FEATURED COMPANIES

Transarterial Chemoembolization (TACE) - Market Size

Transarterial Chemoembolization (TACE) - Market

Report Scope

Scope of Transarterial Chemoembolization (TACE) - Market Report

Chapter Outline

FAQ for this report

What is the Transarterial Chemoembolization (TACE) - Market size in 2030?

Who are the main players in the Transarterial Chemoembolization (TACE) - Market report?

What are the Application segmentation covered in the Transarterial Chemoembolization (TACE) - Market report?

What are the Type segmentation covered in the Transarterial Chemoembolization (TACE) - Market report?

FEATURED COMPANIES

RELATED REPORTS